ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.51 2.06M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 3.95p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.06 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.51.

Evgen Pharma Share Discussion Threads

Showing 7476 to 7500 of 13025 messages
Chat Pages: Latest  305  304  303  302  301  300  299  298  297  296  295  294  Older
DateSubjectAuthorDiscuss
17/2/2021
19:50
The exploratory objectives plus lots of other information are detailed here in case anybody was wondering where MM got the info above:
on target
17/2/2021
18:41
Prof Chalmers lab have been involved in the following study published today, and their research and new observations on neutrophils, implicated in multiple inflammatory diseases, could be of significance to Prof Chalmers upcoming interim data analysis on SFX-01's efficacy, given that their study is also part of the Covid/Ards trial. Gla :-)


James D Chalmers Retweeted

The Lancet Respiratory Medicine

@LancetRespirMed

·

1h

NEW Research—Neutrophil extracellular traps are a key marker of disease severity and treatment response in #bronchiectasis

ProfJDChalmers

·

1h

An international collaborative study involving patients from UK, Spain, Italy and Australia and an incredible collaborative team


Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an...

thelancet.com

Log in

ARTICLES|ONLINE FIRST

Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study




Summary

Background

Bronchiectasis is predominantly a neutrophilic inflammatory disease. There are no established therapies that directly target neutrophilic inflammation because little is understood of the underlying mechanisms leading to severe disease. Neutrophil extracellular trap (NET) formation is a method of host defence that has been implicated in multiple inflammatory diseases. We aimed to investigate the role of NETs in disease severity and treatment response in bronchiectasis.





........

Exploratory objectives of SFX-01's Covid/Ards trial.

Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells

Neutrophil functional studies in isolated cells

Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood

moneymunch
17/2/2021
17:23
It will blow lateral flow out of the water ..... anything diagnostic I'm on it ... Sheffield university involved.
amaretto1
17/2/2021
17:21
U all need to look at BRH Braveheart .....If there test results due early next week are successful ....Imo it's what the Goverment are going to use ... and announce this next week .Very accurate 5 min test !!Problem... very difficult to buy shares in them :-(
amaretto1
17/2/2021
17:04
They'll have to wait for the open offer deadline before confirming any excess shares.
on target
17/2/2021
17:03
On to the other 85k
amaretto1
17/2/2021
17:02
Yes ... I've added another 100k !!May get them may not
amaretto1
17/2/2021
15:21
Is the entitlement usually only 1:11 though brasso?
on target
17/2/2021
14:30
You always get extra shares in these offerings.
brasso3
17/2/2021
14:12
Yep, but i've got a feeling demand will outstrip supply and so might be a struggle getting extra. Gl ;-)
moneymunch
17/2/2021
13:47
Got my allocation rights in HL , is anyone applying for more?
markth126
17/2/2021
13:45
Yep, but presumably the majority of transactions to take them back over 3% were in by the 10th???
moneymunch
17/2/2021
13:37
12/2 is too late for the entitlement, had to be in by the 10th.
on target
17/2/2021
12:58
Hi On Target, presumably pi's who use Intratrader platform, who wanted back in to qualify for the 8p entitlement...we probably won't get disclosure of those that have taken a share of the £10m until after 4th March, admission day. Gl ;-)
moneymunch
17/2/2021
12:37
Ha Rb, sorry i’d missed the Intertrader RNS!
bumpa33
17/2/2021
12:30
Doesn't look related to the placing because it hasn't happened yet, and the RNS says they increased on 12/2.
on target
17/2/2021
12:28
I think so bocker, it just wouldn't make any sense in these unprecedenteded times to waste valuable time and resources on a drug that doesn't work, and so no surprise and the obvious reason why Prof Chalmers will assess SFX 01's efficacy from the interim data....which we now await with great excitement. :-)
moneymunch
17/2/2021
12:16
The Inter Trader holdings position :)
riggerbeautz
17/2/2021
12:11
You’ve lost me Rb...?!
bumpa33
17/2/2021
12:08
Thought you had been adding to your Gibraltar holding for a minute lol
riggerbeautz
17/2/2021
12:05
Rb - yep, time to sit on hands from here on in.
bumpa33
17/2/2021
11:50
Post 75 MM - yes its just common sense isn't it!
bocker01
17/2/2021
11:36
A long term hold with undoubted Transformational upside potential, near , mid and long term. Gla :-)
moneymunch
Chat Pages: Latest  305  304  303  302  301  300  299  298  297  296  295  294  Older

Your Recent History

Delayed Upgrade Clock